BeOne Medicines Ltd.

Alpha Score of 35 reflects weak overall profile with moderate momentum, poor value, weak quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.

BeOne Medicines, Ltd. American Depositary Receipt represents ownership in BeOne Medicines Ltd., a Switzerland-domiciled global oncology company headquartered in Cambridge, Massachusetts with corporate operations there and primary offices in Basel, Switzerland. The company discovers, develops, and commercializes innovative cancer treatments aimed at hematologic malignancies and solid tumors, including blood cancers, lung, breast, gastrointestinal, and rare cancers. Its portfolio features approved therapies like Brukinsa (zanubrutinib), a Bruton's tyrosine kinase inhibitor, and Tevimbra (tislelizumab), a PD-1 inhibitor used in combination regimens for various indications. BeOne Medicines advances a broad pipeline encompassing small molecules, monoclonal antibodies, antibody-drug conjugates, cell therapies, gene therapies, and novel inhibitors such as BCL2, CDK, KRAS, and PRMT5 targets. With one of the largest oncology research teams worldwide, it conducts global clinical trials internally without reliance on contract research organizations, operating across six continents in over 45 countries to enhance patient access to transformative medicines. Founded in 2010, BeOne Medicines maintains strategic partnerships with leading pharmaceutical firms to bolster its development and commercialization efforts in the competitive oncology market.